Page 4 - Kidney Cancer Session

Updates from first line studies

• Abstract 4513 - Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as

first-line therapy for advanced clear cell renal cell carcinoma (ccRCC):

Analysis of progression after first subsequent therapy in KEYNOTE-426. T

Powles et al.

• Abstract 4514 - Impact of subsequent therapies in patients (pts) with

advanced renal cell carcinoma (aRCC) receiving lenvatinib plus

pembrolizumab (LEN + PEMBRO) or sunitinib (SUN) in the CLEAR study. M

Voss et al.

• Abstract 4501 - Association between depth of response (DepOR) and

clinical outcomes: Exploratory analysis in patients with previously untreated

advanced renal cell carcinoma (aRCC) in CheckMate 9ER. C Suarez et al.